February 27, 2024 10:41 AM EST

Roche is 'evaluating potential options' for IPF drug Esbriet as generics gain traction

Kyle LaHucik

Senior Reporter

Roche is looking to offload its idiopathic pulmonary fibrosis drug Esbriet as more patients with the fatal lung disease opt for generic versions and Big …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche is 'evaluating potential options' for IPF drug Esbriet as generics gain traction

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Roche is 'e­val­u­at­ing po­ten­tial op­tion­s' for IPF drug Es­bri­et as gener­ics gain trac­tion

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Roche is 'evaluating potential options' for IPF drug Esbriet as generics gain traction

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra